Most Read Articles
Audrey Abella, 15 May 2020
In adults with atrial fibrillation (AF) after percutaneous coronary intervention (PCI), dual therapy (direct oral anticoagulant [DOAC] + P2Y12 inhibitor) reduces the risk of bleeding compared with triple therapy (vitamin K antagonist [VKA] + DAPT* [aspirin and P2Y12 inhibitor]), a meta-analysis has shown. However, its effects on the risks of mortality and ischaemic endpoints** remain unclear.
09 May 2020
Use of aspirin during the implantation window of the menstrual cycle appears to increase fecundability, reveals a recent study.
Rachel Soon, 08 Apr 2020

Guidelines for local pharmacists on what actions to take during the COVID-19 pandemic have been issued by the Malaysian Pharmaceutical Society (MPS).

Pearl Toh, 26 Sep 2019
The Singapore Health Sciences Authority (HSA) has recalled eight brands of ranitidine products containing trace amounts of the nitrosamine impurity NDMA*, which is a potential human carcinogen.

Vismodegib holds therapeutic potential in advanced basal cell carcinoma

10 Jan 2020

The Hedgehog pathway inhibitor vismodegib appears to be effective in the treatment of locally advanced periocular basal cell carcinoma (BCC), with adverse events (AEs) that are mostly manageable, as reported in a recent study.

The researchers reviewed the medical records of 21 patients (median age, 76 years; 76.2 percent male) with locally advanced and metastatic orbital (n=15) or periocular (n=6) BCC treated with vismodegib. Treatment went on for a median of 9 months.

Follow-up duration was 26 months overall and 17 months after cessation of treatment. Complete response was seen in 10 patients and partial response in another 10 patients, whereas disease remained stable in the remaining patient. Among the complete responders, five sustained a complete response at 16 months and three who stopped treatment experienced recurrence 8 months later.

Most treatment-related adverse reactions were low grade (grade 1 or 2). Frequently reported grade 1 or 2 complications were muscle spasm (76 percent), dysgeusia (57 percent), alopaecia (47 percent), weight loss (47 percent) and reduced appetite (19 percent). Hepatoxicity was the only documented high-grade (grade 3 or 4) adverse event (10 percent).

Treatment was withdrawn in eight patients due to side effects. There were five deaths overall, most of which were deemed unrelated to vismodegib therapy, except for one patient who died from potentially treatment-related sepsis (grade 5 adverse event).

The present data show that long periods of complete tumour regression can be achieved in some patients even after discontinuation of the medication, according to the researchers. However, the optimal treatment protocol and duration have yet to be established, highlighting a need for more prospective multicenter trials.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Audrey Abella, 15 May 2020
In adults with atrial fibrillation (AF) after percutaneous coronary intervention (PCI), dual therapy (direct oral anticoagulant [DOAC] + P2Y12 inhibitor) reduces the risk of bleeding compared with triple therapy (vitamin K antagonist [VKA] + DAPT* [aspirin and P2Y12 inhibitor]), a meta-analysis has shown. However, its effects on the risks of mortality and ischaemic endpoints** remain unclear.
09 May 2020
Use of aspirin during the implantation window of the menstrual cycle appears to increase fecundability, reveals a recent study.
Rachel Soon, 08 Apr 2020

Guidelines for local pharmacists on what actions to take during the COVID-19 pandemic have been issued by the Malaysian Pharmaceutical Society (MPS).

Pearl Toh, 26 Sep 2019
The Singapore Health Sciences Authority (HSA) has recalled eight brands of ranitidine products containing trace amounts of the nitrosamine impurity NDMA*, which is a potential human carcinogen.